Christopher Cannon/LinkedIn
Feb 16, 2026, 13:21
Christopher Cannon: Factor XIa Inhibition Reduces Stroke Risk in Non-Cardioembolic Stroke and High-Risk TIA
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared a post on LinkedIn:
”Factor XIa inhibition works! When added to antiplatelet therapy for non-cardioembolic ischemic stroke or high-risk TIA, XIa inhibition significantly reduced stroke by 26%, with no significant increase in bleeding!”
Title: Next-Generation Factor XIa Cuts Recurrent Stroke Risk by 26%— Asundexian prevented repeat strokes without bleeding side effects
Authors: Nicole Lou
Read the Full Article on MedPage Today։
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 2, 2026, 18:16Saravanan Subramaniam: How Extracellular Histones Act as Key Drivers of Thromboinflammation
-
Apr 2, 2026, 18:06Rob Molhoek Brings Invaluable Insights on Stroke Awareness and Care Improvements – Stroke Foundation
-
Apr 2, 2026, 17:21Paul Bolaji: Phase 2 of the Nigeria National Stroke Registry Is Now Live
-
Apr 2, 2026, 17:13Catherine Jennings: Marking Today as an Important Step Forward for Patients With PE
-
Apr 2, 2026, 17:11Arun V. J: Our Clinical Audit on Transfusion Safety Selected for Presentation at CAHOCON 2026
-
Apr 2, 2026, 17:10Maxime Dely: Better Collection, Better Blood – The Quality Starts Now
-
Apr 2, 2026, 17:09Arun Danewa: Saving a Bone Marrow Patient from Hidden Enemy – TA-TMA
-
Apr 2, 2026, 17:07Cathy Harrison: The WFH Nurses Committee are Looking for New Members
-
Apr 2, 2026, 16:30Sam K. Saha: The Hardest Cases Are the Ones You Can’t Save